Core Viewpoint - Ant Group's AI health application AQ has launched an initiative for the Double Ninth Festival, advocating for better management of chronic diseases among the elderly, highlighting the need for societal attention to this health issue [1][2]. Group 1: Elderly Population and Health Challenges - By the end of 2024, the elderly population (aged 60 and above) in China is expected to reach 310 million, accounting for 22% of the total population, with projections indicating it will exceed 400 million by 2035 [2]. - Chronic diseases, particularly hypertension, diabetes, and hyperlipidemia, are significant health threats to the elderly, with a hypertension prevalence rate of 49% among those aged 60 and above, but only a 7.6% control rate [1][2]. - Over 60% of elderly individuals live alone or only with a spouse, complicating health management [2]. Group 2: AQ's New Features and Solutions - AQ has introduced several features aimed at improving chronic disease management for the elderly, including smart blood pressure and blood glucose monitoring, which provide immediate alerts for abnormal health data [3]. - The collaboration with Yuyue to launch an AI blood pressure monitor allows for automatic data synchronization and the generation of health reports for better long-term management [3]. - A medication reminder function has been implemented, ensuring both parents and children receive notifications to reduce missed doses, thereby preventing health deterioration [3]. - Health records can be shared with family members, enabling children to monitor their parents' medical history and test results, fostering a supportive health management environment even from a distance [3].

据国家卫健委、中国疾控中心数据显示，慢性病死亡人数已占居民总死亡的88.5%，中国60岁及以上老 年人群中，75.8%的人被1种及以上慢性病困扰。AQ披露的一组数据更折射出老年群体的真实困境：AQ 上，60岁以上用户占了近20%；12%的老人会用AQ拍摄药盒，希望看懂药物成分和用法；老人们也会 通过语音反复咨询慢病护理知识，从"冠心病注意事项"到"糖尿病饮食指南"……他们既为身体不适担 忧，也亟需更多有效的帮助，比如在偶尔漏吃药或忘测血压的时候给予提醒。 经济观察网 10月27日，蚂蚁集团AI健康应用AQ发起重阳节倡议《别让慢性病抢走我们的父母》，呼吁 全社会将敬老爱老延伸至老年慢病管理这一健康问题，并推出AI拍血压血糖、家人健康风险预警、慢 病用药定时提醒等5项产品新功能，帮助子女将说不出口的担心，变成真切的关心。 ...

Investment Rating - The report maintains a "Buy" rating for the company, expecting the stock price to outperform the industry index by over 15% in the next six months [5][20]. Core Views - The company is experiencing short-term pressure on revenue, but initial results from brand and channel empowerment are showing effectiveness [1]. - The acquisition of a 51% stake in China Resources Shenghuo has been integrated into the company's financials, leading to a projected revenue of 8.401 billion yuan for 2024, reflecting a year-on-year growth of 9.07% [1][2]. - The company is focusing on "chronic disease management" and aims to become a leader in the "silver health industry" and "chronic disease management" [9]. Financial Performance Summary - Revenue and Profit Projections: - 2023A: Revenue of 8,430 million yuan, net profit of 541 million yuan - 2024A: Revenue of 8,401 million yuan, net profit of 648 million yuan - 2025E: Revenue of 9,214 million yuan, net profit of 749 million yuan - 2026E: Revenue of 10,220 million yuan, net profit of 914 million yuan - 2027E: Revenue of 11,316 million yuan, net profit of 1,121 million yuan [1][9]. - Growth Rates: - Revenue growth rates are projected at 1.8% for 2023, -0.3% for 2024, and 9.7% for 2025 [1]. - Net profit growth rates are projected at 41.1% for 2023, 19.9% for 2024, and 15.6% for 2025 [1]. - Profitability Metrics: - Gross margin for 2024 is projected at 43.46%, with a net profit margin of 7.71% [3]. - Return on Equity (ROE) is expected to improve from 8.1% in 2023 to 14.0% by 2027 [1]. Segment Performance Summary - Revenue by Segment for 2024: - Oral preparations: 36.93 billion yuan, up 1.18% year-on-year - Injection preparations: 5.39 billion yuan, down 49.09% year-on-year - Pharmaceutical wholesale and retail: 36.55 billion yuan, up 6.07% year-on-year [2]. - Key Products: - The core products in the oral preparations segment, including "Kunchinese Medicine 1381" and others, have shown a combined growth of 20% [2]. - The company is enhancing its brand and channel strategies to solidify its market position [4].